OBJECTIVE: Rare cancers have been traditionally understudied, reducing the progress of research and hindering decisions for patients, physicians, and policy makers. We evaluated the descriptive epidemiology of rare cancers using a large, representative, population-based dataset from cancer registries in the United States. METHODS: We analyzed more than 9 million adult cancers diagnosed from 1995 to 2004 in 39 states and two metropolitan areas using the Cancer in North America (CINA) dataset, which covers approximately 80% of the U.S. population. We applied an accepted cancer classification scheme and a published definition of rare (i.e., fewer than 15 cases per 100,000 per year). We calculated age-adjusted incidence rates and rare/non-rare incidence rate ratios using SEER*Stat software, with analyses stratified by gender, age, race/ethnicity, and histology. RESULTS: Sixty of 71 cancer types were rare, accounting for 25% of all adult tumors. Rare cancers occurred with greater relative frequency among those who were younger, nonwhite, and of Hispanic ethnicity than among their older, white, or non-Hispanic counterparts. CONCLUSIONS: Collectively, rare tumors account for a sizable portion of adult cancers, and disproportionately affect some demographic groups. Maturing population-based cancer surveillance data can be an important source for research on rare cancers, potentially leading to a greater understanding of these cancers and eventually to improved treatment, control, and prevention.
OBJECTIVE:Rare cancers have been traditionally understudied, reducing the progress of research and hindering decisions for patients, physicians, and policy makers. We evaluated the descriptive epidemiology of rare cancers using a large, representative, population-based dataset from cancer registries in the United States. METHODS: We analyzed more than 9 million adult cancers diagnosed from 1995 to 2004 in 39 states and two metropolitan areas using the Cancer in North America (CINA) dataset, which covers approximately 80% of the U.S. population. We applied an accepted cancer classification scheme and a published definition of rare (i.e., fewer than 15 cases per 100,000 per year). We calculated age-adjusted incidence rates and rare/non-rare incidence rate ratios using SEER*Stat software, with analyses stratified by gender, age, race/ethnicity, and histology. RESULTS: Sixty of 71 cancer types were rare, accounting for 25% of all adult tumors. Rare cancers occurred with greater relative frequency among those who were younger, nonwhite, and of Hispanic ethnicity than among their older, white, or non-Hispanic counterparts. CONCLUSIONS: Collectively, rare tumors account for a sizable portion of adult cancers, and disproportionately affect some demographic groups. Maturing population-based cancer surveillance data can be an important source for research on rare cancers, potentially leading to a greater understanding of these cancers and eventually to improved treatment, control, and prevention.
Authors: Adora Fou; Freya R Schnabel; Diane Hamele-Bena; Xiao-Jun Wei; Bin Cheng; Mahmoud El Tamer; Laura Klein; Kathie Ann Joseph Journal: Am J Surg Date: 2006-10 Impact factor: 2.565
Authors: Oscar Zurriaga Lloréns; Carmen Martínez García; Vanessa Arizo Luque; Maria José Sánchez Pérez; Julián Mauro Ramos Aceitero; Maria José García Blasco; Maria José Ferrari Arroyo; Lilisbeth Perestelo Peréz; Enrique Ramalle Gómara; Maria Luisa Martínez Frías; Manuel Posada de la Paz Journal: Rev Esp Salud Publica Date: 2006 May-Jun
Authors: Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger Journal: Blood Date: 2007-03-27 Impact factor: 22.113
Authors: Anne Kricker; Bruce K Armstrong; Ann Maree Hughes; Chris Goumas; Karin Ekström Smedby; Tongzhang Zheng; John J Spinelli; Sylvia De Sanjosé; Patricia Hartge; Mads Melbye; Eleanor V Willett; Nikolaus Becker; Brian C H Chiu; James R Cerhan; Marc Maynadié; Anthony Staines; Pierluigi Cocco; Paolo Boffeta Journal: Int J Cancer Date: 2008-01-01 Impact factor: 7.396
Authors: Roman Groisberg; David S Hong; Jason Roszik; Filip Janku; Apostolia M Tsimberidou; Milind Javle; Funda Meric-Bernstam; Vivek Subbiah Journal: Mol Cancer Ther Date: 2018-04-13 Impact factor: 6.261
Authors: Connor J Kinslow; Samuel S Bruce; Ali I Rae; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Adam M Sonabend; Tony J C Wang Journal: J Neurooncol Date: 2018-02-09 Impact factor: 4.130
Authors: A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Shumei Kato; Nithya Krishnamurthy; Kimberly C Banks; Pradip De; Kirstin Williams; Casey Williams; Brian Leyland-Jones; Scott M Lippman; Richard B Lanman; Razelle Kurzrock Journal: Cancer Res Date: 2017-06-22 Impact factor: 12.701
Authors: Monica M Bertagnolli; Charles D Blanke; Walter J Curran; Douglas S Hawkins; Robert S Mannel; Peter J O'Dwyer; Mitchell D Schnall; Norman Wolmark Journal: Cancer Date: 2020-09-24 Impact factor: 6.860